What Is a PDUFA Date? Meaning, Timeline and What Happens to the Stock
A PDUFA date is the deadline the FDA sets for itself to decide on a new drug application. By that date it either approves the drug or sends a Complete Response Letter saying it can't approve it yet. The name comes from the Prescription Drug User Fee Act, the law under which drug companies pay fees in return for a fixed review timeline.
PDUFA date meaning, in plain words
When a company files a new drug application (an NDA) or a biologics application (a BLA), the FDA commits to a target date for its answer. That target is the PDUFA date, also called the PDUFA goal date or action date.
For most brand-new drugs, a standard review takes about 10 months and a priority review about 6 months, counted from when the FDA accepts the filing. Since the FDA takes about two months to accept a filing, the decision usually comes roughly a year after the company submits, or about eight months for a priority review.
One thing surprises new investors: the FDA does not publish a list of upcoming PDUFA dates. The companies announce them, usually in a press release or an SEC filing. Calendars like ours collect them from there.
PDUFA date vs approval date
The PDUFA date is a deadline, not an appointment. The FDA can act early, and it often does. In the 60 recent approvals in our records where both dates are known, about 6 in 10 came before the PDUFA date.
The date can also slip. If the company sends a major amendment late in the review, the FDA can extend the goal date by three months. And the answer on the day is not always yes: it can be a Complete Response Letter.
What happens to the stock before and after a PDUFA date
Most people watch the day itself. Our data says you should watch the weeks before and after too. We looked at 1,191 FDA approvals since 2015 and 231 Complete Response Letters, with the stock price before, during and after each decision.
Before. About 1 in 5 approved stocks had already risen 20% or more in the 90 trading days before the decision. The run-up is where a lot of the move happens.
On the news. Across the two days around an approval, the median move was about zero, and the stock was lower afterwards 47% of the time. Good news that everyone expected is often already in the price.
After a rejection. CRLs are different. The stock fell on the news about 3 times in 4. The worst cases were stocks that had run up first: in the 28 cases where a stock had risen 30% or more in the 60 trading days before a rejection, the median drop on the news was about 25%, and 20 days later it was about 32% lower than before the news.
These numbers include big pharma companies, where one drug barely moves the stock. Small biotechs with one product swing much harder in both directions.
Two real PDUFA dates, and how they played out
UroGen (URGN), June 2025. An FDA advisory panel voted 4 to 5 against UroGen's bladder cancer drug in May, and the stock fell from $9.85 to a low of $3.93. The FDA approved the drug anyway on June 12, one day before its PDUFA date. The stock rose 51.8% that day and kept going: by late November it was near $29.
Nuvation Bio (NUVB), June 2025. Its lung cancer drug was approved on June 11, twelve days early. The stock fell after the approval, from $2.20 to $1.79 within a week. Then sales started, and by late November it was above $8.
Same month, two approvals, two very different first weeks. The point is not that one was predictable. It is that the decision day is only one part of the story.
How to use a PDUFA calendar
- Find the decisions coming up in the next one to four months.
- For each one, check the company's cash. Can it survive a rejection without selling shares at a low price?
- Check who owns the stock and whether it has already run up into the date.
- Look at the company's past FDA decisions and how its stock reacted.
In our test, biotechs with a dated FDA event in the next four months rose 50% or more within six months 19% of the time, against 13% for other biotechs. That is an edge in the odds, not a promise.
See it live: Every upcoming FDA decision, with the company's cash, burn rate, insider and hedge fund activity and short interest in the same row.
Open the FDA Calendar →Watch the video walkthrough
Prefer YouTube? Watch it there.
Frequently asked questions
PDUFA stands for the Prescription Drug User Fee Act, a US law first passed in 1992. It lets the FDA collect fees from drug companies, and in return the FDA commits to review timelines, which is where the PDUFA date comes from.
Yes. The PDUFA date is a deadline, and early decisions are common. In our records of recent approvals where both dates are known, about 6 in 10 came before the PDUFA date. Nuvation Bio's lung cancer drug, for example, was approved 12 days early in June 2025.
No. The FDA generally cannot confirm that an application exists until the company makes it public. PDUFA dates come from the companies themselves, in press releases and SEC filings, and calendars collect them from there.
It is rare but it happens, usually because of extra information requests, inspections or staffing problems. The company normally announces the delay. A missed date is not a rejection, but it adds uncertainty and the stock often reacts.
Not as often as people expect. In our records of 1,191 FDA approvals since 2015, the median move over the two days around the news was about zero, and the stock was lower afterwards 47% of the time. Much of the move tends to happen in the weeks before the decision.
There is no fixed time. Companies often announce after the market closes or before it opens, and the decision can come days before the listed date.
Educational content only. Not financial advice. Past results don't predict future ones.